Digital whole-slide imaging of changes in amyloid after peripheral blood stem cell transplantation in patients with amyloid light-chain amyloidosis

Pathol Int. 2024 Sep;74(9):508-519. doi: 10.1111/pin.13466. Epub 2024 Jul 17.

Abstract

Peripheral blood stem cell transplantation (PBSCT) has made amyloid light-chain (AL) amyloidosis treatable. After PBSCT, hematological complete remission (HCR) can be achieved, leading to improved renal prognosis. The purpose of this study was to evaluate whether whole slide imaging of biopsy samples shows a post-treatment reduction in amyloid deposits in patients with AL amyloidosis. Patients were divided into three groups: Group A (n = 8), not eligible for PBSCT and treated with other therapies; Group B (n = 11), treated with PBSCT and achieved HCR; and Group C (n = 5), treated with PBSCT but did not achieve HCR. Clinical findings and amyloid deposition in glomeruli, interstitium, and blood vessels were compared before and after treatment using digital whole-slide imaging. Proteinuria and hypoalbuminemia improved more in Group B than in the other groups, and in Group B, amyloid deposition improved more in the glomeruli than in the interstitium and blood vessels. The long-term renal and survival prognosis was better in Group B than in the other groups. PBSCT can be expected to improve long-term clinical and renal histological prognosis in patients with AL amyloidosis who achieve HCR. Amyloid disappearance from renal tissue may take a long time even after clinical HCR.

Keywords: AL amyloidosis; hematological complete remission; peripheral blood stem cell transplantation; whole‐slide imaging.

MeSH terms

  • Adult
  • Aged
  • Amyloid* / metabolism
  • Amyloidosis / diagnosis
  • Amyloidosis / pathology
  • Female
  • Humans
  • Immunoglobulin Light-chain Amyloidosis* / pathology
  • Immunoglobulin Light-chain Amyloidosis* / therapy
  • Kidney / pathology
  • Male
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation* / methods
  • Prognosis

Substances

  • Amyloid